Matthew Beaudet Appointed CEO of Araceli Biosciences
Matt Beaudet, CEO, Araceli Biosciences ● Photo Credit: Araceli Biosciences
PORTLAND, Ore., May 6, 2024 (VSNewsNetwork.com) - Araceli Biosciences, a company specializing in cell-based screening and analysis technologies, has appointed Matthew Beaudet as its new President and Chief Executive Officer. Beaudet brings over two decades of leadership experience within the biotech industry, including significant roles at Molecular Probes, Invitrogen, and Life Technologies, and most recently as CEO of InVivo Biosystems.
During his time at InVivo Biosystems, Beaudet successfully led efforts in fundraising and oversaw the development of key technological innovations, including the commercialization of fluorescence-based assays and instrument platforms.
Bill Cortelyou, Chairman of the Board at Araceli, expressed his endorsement of the new CEO, stating, “The Araceli Board of Directors is confident Matt's proven leadership record, commitment to the Oregon biotechnology community, entrepreneurial spirit, and desire to create cutting-edge technologies empowering researchers to accelerate therapeutic discovery will propel Araceli into a new and exciting era of growth and development.”
Beaudet shared his enthusiasm about his new role, saying, “I am grateful to the Board for trusting me to lead this exceptional team. The innovation and success of the Araceli platform are a testament to what game-changing technology looks like in action. Joining you at this pivotal moment is a tremendous honor, I look forward to working alongside you to transform the speed of drug development and redefine what is possible in our field.”
For more information about Araceli Biosciences, visit www.aracelibio.com.
Source: Araceli Biosciences via Newswire
